# Vonicog alfa PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vonicog-alfa

> The next catalyst for vonicog alfa, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Apr to Jul 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | vonicog alfa |
| Codes | TAK-577 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Von Willebrand Disease (VWD)](https://sec-api.dev/indications/von-willebrand-disease-vwd) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Apr to Jul 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Von Willebrand Disease (VWD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05582993 (A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-11 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05582993

### April 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Von Willebrand Disease (VWD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05582993 (A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-11 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05582993

## Same indication

- [ALN-6400](https://sec-api.dev/pdufa/aln-6400) (ALNY)
- [Vonvendi](https://sec-api.dev/pdufa/vonvendi) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vonicog-alfa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vonicog alfa PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vonicog-alfa

```bibtex
@misc{secapidev_pdufa_vonicog_alfa_20261116,
  title        = {Vonicog alfa PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vonicog-alfa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vonicog_alfa_20261116","title":"Vonicog alfa PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vonicog-alfa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
